Sally Bodensteiner, MD
Family Medicine · Vincennes, INNPI 1851580823
Payments from drug & device makers
Across 285 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$481
- Lilly USA, LLC$395
- Amgen$323
- AstraZeneca$317
- Indivior Inc.$242
- AbbVie$229
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,197100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $481 |
| Lilly USA, LLC | 34 | $395 |
| Amgen(2 entities) | 25 | $323 |
| AstraZeneca | 17 | $317 |
| Indivior Inc. | 15 | $242 |
| AbbVie | 15 | $229 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $192 |
| Avanir Pharmaceuticals, Inc. | 10 | $190 |
| Pfizer | 13 | $173 |
| Otsuka America Pharmaceutical, Inc. | 9 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $132 |
| Axsome Therapeutics, Inc. | 4 | $113 |
| GSK | 8 | $103 |
| Merck | 7 | $91 |
| Vanda Pharmaceuticals Inc. | 3 | $81 |
| Mylan Specialty L.p. | 5 | $80 |
| Johnson & Johnson | 5 | $65 |
| Bayer | 4 | $63 |
| Boehringer Ingelheim | 4 | $62 |
| Novartis | 4 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Organon | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 1 | $30 |
| Hologic Sales And Service, LLC | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Exact Sciences | 2 | $26 |
| Duchesnay USA Incorporated | 2 | $25 |
| Eisai Inc. | 2 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
| Sonex Health, Inc. | 1 | $13 |
| Vivus LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$4,206 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $119,202 |
| TrulicityDulaglutide | 88 | $101,966 |
| EliquisApixaban | 78 | $93,826 |
| FarxigaDapagliflozin Propanediol | 83 | $80,370 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $78,786 |
| MounjaroTirzepatide | 39 | $41,155 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $38,750 |
| RexultiBrexpiprazole | 19 | $37,635 |
| Xigduo XrDapaglifloz Propaned/Metformin | 47 | $36,507 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $35,314 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $33,059 |
| Nucynta ErTapentadol Hcl | 16 | $28,385 |
| LinzessLinaclotide | 49 | $27,512 |
| XareltoRivaroxaban | 33 | $27,235 |
| Repatha SureclickEvolocumab | 28 | $23,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $395 | $143,122127 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $481 | $127,105105 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $103 | $120,653126 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $317 | $115,684117 claims |
| PfizerEliquis | $173 | $93,82678 claims |
| Boehringer IngelheimSynjardy Xr, Stiolto Respimat | $62 | $50,85240 claims |
| AbbVieLinzess, Vraylar | $229 | $42,55561 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $152 | $37,63519 claims |
| Johnson & JohnsonXarelto | $65 | $27,23533 claims |
| MerckJanuvia | $91 | $20,87427 claims |
| NovartisEntresto | $53 | $14,71611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $192 | $5,32114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Vincennes
- Jane BridgesVincennes$28K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.